Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males.

@article{Somma1998BoneMA,
  title={Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males.},
  author={Carolina Di Somma and Annamaria Colao and Antonella di Sarno and Michele Klain and Maria Luisa Landi and G Facciolli and Rosario Pivonello and Nicola Panza and Marco Salvatore and Gaetano Lombardi},
  journal={The Journal of clinical endocrinology and metabolism},
  year={1998},
  volume={83 3},
  pages={807-13}
}
The aim of this prospective study was to evaluate the bone mineral density (BMD) at lumbar spine and femoral neck levels and biochemical parameters of bone turnover in 20 consecutive hyperprolactinemic males before and after an 18-month treatment with different dopamine agonists. Six patients received bromocriptine at a dose of 2.5-10 mg/day; 7 patients received quinagolide at a dose of 0.075-0.3 mg/day; 7 patients received cabergoline at a dose of 0.5-1.5 mg/week. BMD, serum PRL, testosterone… CONTINUE READING
27 Citations
29 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Primary prevention of osteoporosis

  • V Maktovic, JZ Ilich, M Skugor, M. Saracoglu
  • Phys Med Rehab Clin North Am
  • 1995
1 Excerpt

Similar Papers

Loading similar papers…